Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

Conclusions
Natalizumab trough drug levels can decrease after switching from natalizumab intravenous to SC administration. We advise to monitor trough drug levels in patients with low natalizumab drug levels during intravenous treatment, patients with higher body mass index or patients on extended treatment intervals who switch to SC administration of natalizumab.

Source: Journal of Neurology, Neurosurgery and Psychiatry - May 15, 2023 Category: Neurosurgery Authors: Toorop, A. A., van Kempen, Z. L. E., Steenhuis, M., Nielsen, J., Sinnige, L. G. F., van Dijk, G., Roosendaal, C. M., Arnoldus, E. P. J., Hoitsma, E., Lissenberg-Witte, B. I., de Jong, B. A., Oosten, B. W. v., Strijbis, E. M. M., Uitdehaag, B. M. J., Rispe Tags: JNNP Patients' choice Multiple sclerosis Source Type: research